Introduction
Salmonellae are one of the most common causes of food-borne illness in humans. The typhoidal Salmonella, such as Salmonella enterica serovar Typhi (S. Typhi) and S. Paratyphi, only colonise humans and are usually acquired by the consumption of food or water contaminated with human faecal material. [1] The symptoms of paratyphoid fever are similar to those of typhoid fever, but are generally milder with shorter incubation periods and a much lower case fatality rate. [2] The incidence of enteric fever caused by S. Paratyphi A has been increasing in South-East Asia, South Africa and the Indian subcontinent, with S. Paratyphi A now increasing prevalence of antimicrobial resistant S. Paratyphi A isolates in this region of India.
Methods
Blood cultures from a total of 3744 patients presenting with fever at the Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry and Government General Hospital, Pondicherry during January 2005 to December 2009 were taken for microbial diagnosis. The patients ranged in age from 4 years to 69 years (median, 38 years). Standard blood culture protocols and biochemical methods for identification were followed. Isolates confirmed using specific Salmonella antisera (Murex Biotech, England).
Isolates were tested for susceptibility to antimicrobials by the Kirby-Bauer disk diffusion method, using ampicillin (10 μg), cotrimoxazole (25 μg), chloramphenicol (30 μg), ciprofloxacin (5 μg), ceftazidime (30 μg), ceftriaxone (30 μg) and nalidixic acid (10 μg). Escherichia coli ATCC 25922 was used as a control isolate. Nalidixic acid susceptibility was used as a screening test for reduced susceptibility to ciprofloxacin. DCS was defined according to European Committee on Antimicrobial Susceptibility Testing guidelines. [5] Minimum inhibitory concentrations (MICs) were determined by both agar dilution technique and Etest (AB Biodisk, Solna, Sweden) against the antibiotics ciprofloxacin, ampicillin, chloramphenicol and ceftriaxone. MICs against gatifloxacin and ofloxacin were determined by Etest only. The breakpoints for ofloxacin, gatifloxacin and ciprofloxacin were those defined by the Clinical Laboratory Standards Institute, 2011 (CLSI). [6] The ciprofloxacin MIC breakpoints according to CLSI 2012 guidelines has been revised. [7] Testing for antimicrobial resistance via efflux pump activity was performed using the cyclohexane tolerance test, and via the detection of the MIC in the absence and presence of the efflux pump inhibitor (EPI) Phe-Arg-βnaphthylamide (PaβN) at 20 μg/mL. The known positive and negative laboratory-generated control strains were used. [4] Molecular analysis of quinolone resistance was performed on 48 (18 high-level ciprofloxacin resistant and 30 susceptible) isolates. Of the 30 ciprofloxacin susceptible isolates, 3 were nalidixic acid resistant (NAR) and 27 nalidixic acid susceptible (NAS). Known positive and negative laboratorygenerated control strains were used. [4] The molecular mechanism of quinolone resistance was determined by investigating mutations in the quinolone resistance-determining region (QRDRs) of DNA gyrase (gyrA and gyrB) and DNA topoisomerase IV (parC and parE) genes according to previously described protocols. The possible presence of the plasmid-mediated quinolone resistance qnr gene (qnrA, qnrB and qnrS) and aac(6')-Ib-cr gene was determined using polymerase chain reaction (PCR). [4] Sequencing was performed using both forward and reverse primers (same as used for the PCR) on an Eppendorf DNA Thermal Cycler and analysed in an automatic DNA sequencer 3130X1 Genetic Analyser (ABI PRISM) AB. DNA sequences were analysed using commercial software (Lasergene; DNAStar, Inc., Madison, Wis.). The BLASTN program was used for database searching (http://www.ncbi. nlm.nih.gov/BLAST/), and the QRDR DNA sequences were compared with those of S. Typhi isolate Ty2 (GenBank accession no. AE014613).
As a screening control, restriction fragment length polymorphism (RFLP) analysis was performed on PCR amplified 620-bp fragments of the gyrA gene of all isolates. The gyrA gene in S. Paratyphi A possesses 3 HinfI restriction sites, one of which lies at position Ser 83. Therefore, HinfI restriction digestion of the PCR product was performed to detect mutations occurring at Ser 83. [8] PCR screening and sequencing was performed to identify the β-lactamase resistance genes bla TEM , bla SHV , bla OXA-1 group and bla CTX-M . β-lactamase screening was performed for 20 isolates that were highly resistant to ampicillin (MIC ≥256 μg/ml). Isoelectric focusing (IEF) of β-lactamase enzymes was performed using standard methods to determine and characterise β-lactamase activity. Known positive and negative laboratory-generated control strains were used. [4] Genotyping was performed on a representative sample of 40 S. Paratyphi A isolates using pulsed-field gel electrophoresis (PFGE). [4] 
Results

Trends in antimicrobial susceptibility of S. Paratyphi A isolates
A total of 284 S. Paratyphi A isolates from two hospitals recovered during 2005-2009 were included in this study, representing 100% of the S. Paratyphi A isolates recovered during this period. Of these isolates, 217 (76.4%) were fully susceptible to ampicillin, chloramphenicol and cotrimoxazole; 5 (1.7%) were resistant to all first-line antimicrobials, that is, ampicillin, cotrimoxazole and chloramphenicol (multi-drug resistant [MDR]); 281 (98.9%) were (NAR); and 2 isolates were both MDR and NAR. The results are summarised in Table 1 . Eighteen (6.3%) of the isolates possessed high-level resistance (≥4 μg/mL) to ciprofloxacin, and there was a steady decline in the number of MDR isolates over the 5 years study period, as well as a parallel increase in NAR (non-MDR) isolates [ Tables 1 and 2 ].
The susceptibility results for different antibiotics as well as the MIC 50 and MIC 90 (MICs at which 50 or 90% of the isolates were inhibited) values obtained for 284 S. Paratyphi A isolates are shown in Table 3 . The MIC of 18 vol. 34, No. 2 www.ijmm.org contribution to resistance. However, in the presence of EPI, the MIC to ciprofloxacin and nalidixic acid decreased 4-fold in all of the 18 isolates possessing an MIC of ≥4 μg/mL.
Molecular analysis of quinolone resistance
The relationship between ciprofloxacin MIC and nucleotide changes within DNA gyrase and topoisomerase IV subunit genes of 11 isolates, representing different resistance profiles are shown in Table 4 . A single gyrA mutation was observed at Ser 83 in NAR isolates with a comparatively reduced susceptibility to ciprofloxacin (MIC 0.25-1 μg/mL) with no mutations detected in parC. All ciprofloxacin-resistant isolates (MIC up to 8 μg/mL) showed 3 mutations, two mutations within the QRDR of gyrA, at positions 83 and 87; and a single mutation in parC, at position 80. No mutations were detected in QRDRs of gyrA and parC genes of NAS isolates, for which ciprofloxacin MICs were <0.125 μg/mL. Interestingly, isolates with ciprofloxacin MICs of ≥12 μg/mL had 4 mutations, 2 mutations within the QRDR of gyrA, at positions 83 and 87, and 2 mutations also in parC, at positions 57 and 80. The amino acid substitutions found to be associated with resistance to quinolones in the GyrA were at the Ser-83 position, to Tyr or Phe, and in Asp-87 substitution to Gly. The amino acid substitutions found to be associated with resistance to quinolones in the ParC were Thr57→Ser or Ser 80→Arg. Sequence mutations in the QRDRs of gyrB and parE genes were not found in any of the isolates tested.
In some NAS and NAR isolates, irrespective of their MICs against ciprofloxacin (0.015 μg/mL-≤4 μg/mL), a mutation was found outside the QRDR of gyrA. This substitution found outside the QRDR of GyrA was Gly133→Glu. All isolates were negative for qnr (qnrA, qnrB and qnrS) and aac (6')-Ib-cr genes.
Restriction fragment length polymorphisms
RFLP is a simple and economical screening method for the detection of mutations in gyrA. The enzyme Hinfl cuts the amplified 620 bp fragment of the wild-type S. Paratyphi A gyrA gene 3 times. This results in the digestion of the fragment into four sections of lengths. Mutation at serine 83 of the amplified fragment abolishes the Hinfl site, the PCR product is only cut into three fragments. Two RFLP patterns were observed. Pattern A was seen in all 3 NAS (Ciprofloxacin MIC <0.25 μg/mL) tested isolates. It resulted in the digestion of the fragment into four sections of lengths 244 bp, 149 bp, 138 bp and 99 bp, a finding that indicated that there were no alterations of the HinfI restriction sites. Pattern B was seen in 45 isolates. Three fragments of size 343bp, 149bp and 138 bp were seen. All isolates showing this pattern resembled each other in being NAR (with a ciprofloxacin MIC of ≥0.25 μg/mL). high-level ciprofloxacin resistant isolates ranged from 4 μg/ mL (13 isolates) to 32 μg/mL (3 isolates). A parallel increase in MIC was observed against ofloxacin in these isolates in the range of 16-24 μg/mL. However, all had an MIC of <8 μg/ mL against gatifloxacin. For gatifloxacin, the MIC 50 and MIC 90 were 1-2 dilution steps lower than that of ciprofloxacin and ofloxacin with respect to all isolates tested. Ciprofloxacin MICs for susceptible isolates were ranged between 0.016 and 1 μg/mL. A positive correlation was observed between reduced ciprofloxacin susceptibility and NAR in all the isolates. Considering the CLSI 2012 ciprofloxacin breakpoints for resistance (≤1 μg/ml), 75.0% of the isolates were found to be resistant. All of the isolates were found to be susceptible to ceftriaxone, though interestingly there was a gradual increase in MIC 90 values from 0.064 to 0.25 μg/mL for ceftriaxone during during the study period.
Efflux pumps
Using the cyclohexane tolerance test, none of the isolates showed evidence for an efflux pump-mediated
Detection of β-lactamase genes
Three (15%) of 20 (highly resistant to ampicillin) isolates were found to be positive for bla TEM-1 , with IEF experiments showing a β-lactamase with a pI of 5.4 (TEM-1). One of the 20 isolates was positive for bla OXA-1like gene but none of the isolates positive for both bla TEM-1 and bla OXA-1 . Of the 3 bla TEM-1 positive isolates, 2 were also found to be ciprofloxacin resistant.
Genotyping
Forty isolates were selected for PFGE genotyping, being representative of different antibiotic susceptibility profiles. Overall, 3 major PFGE patterns were observed at the 85% similarity level [ Figure 1 ]. However, no association was observed between these major PFGE patterns and antimicrobial resistance profile or date of isolation.
Discussion
The prevalence of paratyphoid fever, caused by S. Paratyphi A, has been increasing worldwide; with studies from India and Nepal suggesting that in some settings, S. Paratyphi A can contribute up to half of all cases of enteric fever. [9] According to Ochiai et al., [10] the highest S. Paratyphi A prevalence is seen in Pakistan, and the lowest S. Paratyphi A incidence is seen in Indonesia. [10] Reports from India have shown an increasing prevalence of S. Paratyphi A in many regions, including the urban slums of New Delhi, Mumbai, Nagpur, Kolkata, South India (Karnataka), North India and Pondicherry. [2, 11] The highest prevalence of S. Paratyphi A infections is from India, reaching 44.9% (between 1994 and 1998) in New Delhi and 47% (between August 2004 and December 2005) in Pondicherry. [11] There was no obvious seasonal variation in the isolation of S. Paratyphi A in this study. In Nepal, the rainy season has a higher incidence. [12] Our data do not support seasonal variation, even though Pondicherry is affected by both dry and rainy seasons.
Antibiotic resistance in S. Paratyphi A isolates is an emerging problem. For example, though a 1996 outbreak of paratyphoid fever in India demonstrated that isolates were susceptible to all antibiotics including chloramphenicol, amoxicillin, cotrimoxazole, gentamicin, ciprofloxacin and ceftriaxone, [13] 2 years later in New Delhi, the prevalence of resistance to ciprofloxacin had increased to 24% with 32% of isolates exhibiting DCS. [14] From the set of isolates in this study, the majority of isolates (76.4%) were fully susceptible to ampicillin, chloramphenicol and cotrimoxazole, though 18 (6.3%) isolates were resistant to ciprofloxacin. Further, almost 2% of isolates were MDR and 98.9% were NAR. Interestingly, there was a steady decline in the number of MDR isolates over the 5 year study period, as well as a parallel increase in NAR (non-MDR) isolates, which could possibly reflect antibiotic prescribing practices in Pondicherry over this period of time.
The QRDR within topoisomerases contains hotspots for mutations around the active site, which are associated with raised MIC values for fluoroquinolones. [4, 15] For gyrA from NAR Salmonella isolates, 2 mutations are most frequently observed in clinical isolates: Ser 83→Phe and Ser 83→Tyr. [4] The association between resistance and mutations in parC is, however, less clear. Consistent with previous publications, the amino acid substitutions found to be associated with resistance to quinolones in GyrA was at the Ser-83 position, to Phe or Tyr, accompanied with the substitution Asp 87→Gly. Amino acid substitutions in ParC (Ser 80→Arg or Thr57→Ser) were also found to be associated with resistance to quinolones, though as previously mentioned, the exact role of these mutations in quinolone resistance is less clear. Interestingly, the In this study, 40 isolates were selected for PFGE genotyping, being representative of different antimicrobial susceptibility profiles. Three different major PFGE patterns were observed at the 85% similarity level for these 40 representative isolates. The literature regarding genotypic clonality in S. Paratyphi infections in India and surrounding countries is mixed. For example, in an outbreak of paratyphoid fever associated with S. Paratyphi A in New Delhi, 5 sporadic cases of S. Paratyphi A gave PFGE patterns following XbaI digestion that were distinct. [16] In contrast, the 13 outbreak isolates shared only 4 closely related PFGE patterns. Similar results were obtained after digestion with a second restriction endonuclease, SpeI. In another study, a total of 39 human isolates of S. Paratyphi A from Pakistan, India, Indonesia and Malaysia were typed by PFGE using XbaI restriction digests. This study suggested that a limited number of clones were responsible for paratyphoid fever in those countries. [17] 
Conclusion
In view of the current antimicrobial susceptibility trend (overall decline in MDR S. Paratyphi A) in Pondicherry, the first-line antimicrobials (ampicillin, chloramphenicol and cotrimoxazole) may be of use again in endemic areas with control over antibiotic use (antibiotic stewardship). [18] A decline in MDR, (probably due to the loss of a highmolecular-weight self-transferable plasmid encoding chloramphenicol, ampicillin and cotrimoxazole resistance) could lead to the cautious reuse of classical first-line antibiotics. In view of the increasing number of infections with S. Paratyphi A, development of a suitable vaccine against S. Paratyphi A is urgently needed, though the ultimate solution to salmonellosis per se would be the provision of good public health, safe water and food sanitation. This situation needs to be urgently addressed in India (not only in Pondicherry). In the very short-term, the use of correct and targeted antibiotic therapy needs to be considered by clinicians when treating typhoidal disease, as well as rapid diagnosis and antimicrobial resistance monitoring. Future publications will indicate the 
